Discovery Laboratories, Inc. Share Price Nasdaq
Equities
US2546684034
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-15 | Windtree Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-17 | Windtree Therapeutics Seeks Acquisitions | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.82M 143M |
---|---|---|---|---|---|
Net income 2024 * | -21M -1.65B | Net income 2025 * | -29M -2.28B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.2
x | P/E ratio 2025 * |
-0.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.99% |
Latest transcript on Discovery Laboratories, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Craig Fraser
CEO | Chief Executive Officer | 59 | 31/01/16 |
Eric Curtis
COO | Chief Operating Officer | 56 | 08/03/20 |
George Cox
CTO | Chief Tech/Sci/R&D Officer | 73 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Scott
BRD | Director/Board Member | 70 | 02/02/21 |
Mark Strobeck
BRD | Director/Board Member | 53 | 21/06/23 |
Leslie Williams
BRD | Director/Board Member | 64 | 02/02/21 |
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |